Given its central role in cancer cell metabolism and survival, PKM2 is considered a promising therapeutic target. Inhibitors of PKM2 aim to lock the enzyme in its less active form, thereby disrupting the metabolic flexibility of cancer cells and reducing their proliferative capacity. Several small molecules and peptides that specifically target PKM2 are currently under investigation in preclinical and clinical studies.
